GlassScriptPhysician profile
Elinor M Anan
NPI 1730177759
$758.32
in general payments reported to CMS, 2019-2025
24 companies · $20.03 in 2025
The $20.03 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $162 · 2023: $123 · 2024: $223 · 2025: $20.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $181.75 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $63.98 | 2023-2024 | Horizant, Horizant |
| Coloplast Corp | $60.14 | 2019-2024 | Speedicath |
| Merz Pharmaceuticals, LLC | $58.14 | 2023-2024 | Xeomin, Inbrija |
| Argenx US, INC. | $53.78 | 2024 | Vyvgart Hytrulo |
| Collegium Pharmaceutical, INC. | $42.25 | 2019-2024 | Xtampza |
| Bioventus LLC | $29.19 | 2024 | L300 Go System |
| Janssen Pharmaceuticals, INC | $25.07 | 2019 | |
| Abbott Laboratories | $20.36 | 2019 | |
| Amgen INC. | $20.03 | 2025 | Repatha |
| Axsome Therapeutics, INC. | $17.95 | 2023 | Sunosi |
| Abbvie INC. | $16.69 | 2023 | Botox |
| Otsuka America Pharmaceutical, INC. | $16.27 | 2023 | Nuedexta |
| Allergan, INC. | $15.83 | 2019 | |
| Lundbeck LLC | $15.52 | 2024 | Vyepti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.14 | 2019 | |
| Biogen, INC. | $14.05 | 2019 | |
| Tersera Therapeutics LLC | $14.04 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.88 | 2024 | Ultomiris |
| Pacira Therapeutics, INC. | $13.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.27 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.93 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elinor Anan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.